Company description

ALIM is a clinical-stage biopharmaceutical company that focuses on developing and commercializing innovative therapies to address unmet medical needs. Founded in 1996, the company is headquartered in San Carlos, California. Their primary focus is on creating novel treatments for chronic liver diseases such as non-alcoholic steatohepatitis (NASH) and other metabolic disorders. Their flagship product, known as ZAEBRYXIS, has received FDA approval for the treatment of moderate to severe acute pain in adults, making it the first non-opioid analgesic approved for both intravenous and oral use. ALIM also has a pipeline of promising drug candidates in various stages of development, targeting diseases such as ulcerative colitis, Crohn's disease, and rheumatoid arthritis. With a team of experienced and dedicated researchers and clinicians, ALIM continues to push the boundaries of pharmaceutical innovation to improve the lives of patients worldwide.